替雷利珠单抗联合GC化疗方案对转移性膀胱癌的疗效及安全性

Efficacy and Safety of Tislelizumab Combined with GC Chemotherapy for Metastatic Bladder Cancer

目的:研究替雷利珠单抗联合GC化疗方案对转移性膀胱癌患者的疗效及安全性。方法:回顾性分析2018年1月—2023年1月蚌埠医科大学第一附属医院收治的80例转移性膀胱癌患者的临床资料,根据治疗方案不同分为对照组(GC方案,n=49)与研究组(替雷利珠单抗联合GC方案,n=31)。比较两组治疗效果、不良反应、肿瘤指标[血管内皮生长因子(vascular endothelial growth factor,VEGF)、基质金属蛋白酶-2(matrix metalloproteinase-2,MMP-2)、γ干扰素(interferon-γ,IFN-γ)]及1年生存率。结果:研究组疾病控制率、1~2级免疫相关性甲状腺功能减退/亢进发生率较对照组高,差异有统计学意义(P<0.05);两组客观缓解率、其余1~2级、3~4级不良反应发生率比较,差异无统计学意义(P>0.05)。研究组治疗后VEGF、MMP-2较对照组低,IFN-γ较对照组高,差异有统计学意义(P<0.05);两组1年生存率比较,差异有统计学意义(P<0.05)。结论:替雷利珠单抗联合GC化疗方案治疗转移性膀胱癌能提升疾病控制效果,改善肿瘤指标,但仍需注意不良反应的发生。

Objective:To study the efficacy and safety of Tirelizumab combined with GC chemotherapy for patients with metastatic bladder cancer.Method:The clinical data of 80 patients with metastatic bladder cancer who admitted to the First Affiliated Hospital of Bengbu Medical University from January 2018 to January 2023 were retrospectively analyzed,they were divided into the control group(GC regimen,n=49)and the study group(Tirelizumab combined with GC regimen,n=31)according to the different treatment regimens.The therapeutic effect,adverse reactions,tumor indicators[vascular endothelial growth factor(VEGF),matrix metalloproteinase-2(MMP-2),interferon-γ(IFN-γ)]and 1-year survival rate were compared between two groups.Result:The disease control rate and the incidence of grade 1-2 immune-related hypothyroidism/hyperthyroidism in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05);there were no significant differences in the objective remission rate and the incidence of adverse reactions of grade 1-2 and grade 3-4 between two groups(P>0.05).The VEGF and MMP-2 in the study group after treatment were lower than those in the control group,and IFN-γwas higher than that in the control group,the differences were statistically significant(P<0.05).There was significant difference in 1-year survival rate between two groups(P<0.05).Conclusion:Tirelizumab combined with GC chemotherapy in the treatment of metastatic bladder cancer can improve the effect of disease control and improve tumor indicators,but it is still necessary to pay attention to the occurrence of adverse reactions.